Neuromodulation offers hope for Chile's treatment-resistant teen depression crisis

In Chile, the numbers land like a weight: three out of every four adolescents carry symptoms of anxiety or depression. Suicide remains among the leading causes of death for people between fifteen and twenty-nine. The crisis is not new, but it is accelerating, and it is reshaping how families understand what it means to raise a teenager in this country.

Javier's daughter Emilia was always emotionally sensitive. Through her childhood, the family moved through therapies and psychiatric treatments, each one a small hope that something would shift. When adolescence arrived, a deep depression settled in. She stopped wanting to take medication. The story is becoming familiar in Chilean households: a young person whose brain does not respond to the standard interventions, whose suffering persists despite the conventional tools.

Doctors call this treatment-resistant depression, and it affects somewhere between a quarter and two-fifths of adolescents with depression. The definition is precise: a teenager who has carried symptoms for more than a year and has already tried at least two different medication regimens over six to eight weeks without meaningful improvement. Dr. María José Arroyo, a child and adolescent psychiatrist at Brain Treatment Center Chile, explains that treatments should begin showing change within the first weeks—shifts in daily functioning, social integration, improvements in sleep and appetite. When those changes do not come, families face a narrowing path.

Into this gap has stepped a technology called Transcranial Magnetic Stimulation, or TMS. It is not a drug. It is not talk therapy. Instead, it uses magnetic pulses to stimulate specific regions of the brain involved in mood regulation. The FDA approved it for patients as young as fifteen with treatment-resistant depression. The procedure is non-invasive, painless, and delivered in defined sessions after specialized medical evaluation. According to Dr. Arroyo, approximately seventy percent of patients respond positively to TMS, compared to the forty percent who do not respond to medication alone. Beyond efficacy, there is another advantage: the absence of the side effects that often accompany psychiatric drugs—weight gain, sexual dysfunction, emotional blunting—the collateral damage that sometimes makes the cure feel as heavy as the illness.

The science backs the clinical observation. Studies published in Clinical Neurophysiology document that TMS achieves depression remission in forty-one percent of patients, reduces anxiety significantly in one of every three adolescents, and diminishes suicidal thinking in more than sixty percent of cases. Some patients notice improvement within the first week.

For Javier, the change was visible and sudden. After TMS, his daughter began to shift. The desmotivation that had hollowed her out started to lift. She became animated again, affectionate. Her concentration returned. Her daily rhythms reorganized themselves. He describes it as recovering his daughter—the joyful, engaged person who had been buried under the weight of her own brain chemistry.

This is not a cure-all story. TMS is expensive, not universally covered by insurance, and access remains limited in Chile. But for families exhausted by failed treatments and the constant shadow of suicide risk, it represents something concrete: a door that had seemed closed beginning to open. The question now is whether Chile's health system will recognize the urgency and make this option available to the thousands of adolescents for whom conventional treatment has failed. The crisis is not slowing. The need for alternatives is not theoretical.